| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
- Chowdhury, F., et al.
(författare)
-
A phase I/II study to evaluate safety, tolerability and immunogenicity of Hillchol®, an inactivated single Hikojima strain based oral cholera vaccine, in a sequentially age descending population in Bangladesh
- 2021
-
Ingår i: Vaccine. - : Elsevier BV. - 0264-410X. ; 39:32, s. 4450-4457
-
Tidskriftsartikel (refereegranskat)abstract
- Background: The World Health Organization (WHO) recommends the use of oral cholera vaccines (OCVs) as part of an integrated control program, both in highly endemic settings and during cholera epidemics. The available and internationally recommended WHO-prequalified OCVs (Dukoral, Shanchol, Euvichol) contain multiple heat and formalin-killed V. cholerae strains of Inaba and Ogawa serotypes. MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd. in technical collaboration with University of Gothenburg, Sweden has developed a new single strain OCV, Hillchol. This vaccine consists of formaldehyde-inactivated whole cell El Tor V. cholerae O1 bacteria engineered into the Hikojima serotype for stable expression of both the Ogawa (AB) and Inaba (AC) LPS antigens on the bacterial surface. We evaluated the safety and immunogenicity of this novel and potentially much less expensive OCV in comparison with Shanchol. Methods: We conducted a randomized, non-inferiority, age-descending clinical trial of OCV (Hillchol vs. Shanchol) in the Mirpur area of Dhaka city from July 2016 to May 2017. This study was carried out in three different age cohorts (1–<5, 5–17 and ≥18 years old). Two doses of vaccine were given at 14 days intervals to 560 healthy participants. Findings: No serious adverse events were reported. There were no significant differences in the rates of adverse events between the test vaccine (Hillchol) and the comparator (Shanchol) group. Serum vibriocidal antibody responses in all age groups combined were comparable for all the O1 Ogawa (59% vs. 67%; 90% CI of difference: −14.55, −0.84) and Inaba (70% vs. 71%; 90% CI of difference: −7.24, 5.77) serotypes, showing that the Hillchol vaccine was non-inferior to Shanchol. This new vaccine was also non-inferior to Shanchol in the different age strata. Conclusion: The safety and immunogenicity profile of the new OCV Hillchol is comparable to Shanchol in persons residing in a cholera-endemic setting. ClinicalTrials.gov number: NCT02823899. © 2021
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
|
|
| 11. |
|
|
| 12. |
|
|
| 13. |
|
|
| 14. |
|
|
| 15. |
|
|
| 16. |
- Ambikan, Anoop T., et al.
(författare)
-
Multi-omics personalized network analyses highlight progressive disruption of central metabolism associated with COVID-19 severity
- 2022
-
Ingår i: Cell systems. - : Elsevier BV. - 2405-4712 .- 2405-4720. ; 13:8, s. 665-681
-
Tidskriftsartikel (refereegranskat)abstract
- The clinical outcome and disease severity in coronavirus disease 2019 (COVID-19) are heterogeneous, and the progression or fatality of the disease cannot be explained by a single factor like age or comorbidities. In this study, we used system-wide network-based system biology analysis using whole blood RNA sequencing, immunophenotyping by flow cytometry, plasma metabolomics, and single-cell-type metabolo-mics of monocytes to identify the potential determinants of COVID-19 severity at personalized and group levels. Digital cell quantification and immunophenotyping of the mononuclear phagocytes indicated a sub-stantial role in coordinating the immune cells that mediate COVID-19 severity. Stratum-specific and person-alized genome-scale metabolic modeling indicated monocarboxylate transporter family genes (e.g., SLC16A6), nucleoside transporter genes (e.g., SLC29A1), and metabolites such as a-ketoglutarate, succi-nate, malate, and butyrate could play a crucial role in COVID-19 severity. Metabolic perturbations targeting the central metabolic pathway (TCA cycle) can be an alternate treatment strategy in severe COVID-19.
|
|
| 17. |
|
|
| 18. |
|
|
| 19. |
- Eriksson, M, et al.
(författare)
-
Associations between parents' and 12-year-old children's sport and vigorous activity: the role of self-esteem and athletic competence
- 2008
-
Ingår i: Journal of physical activity & health. - : Human Kinetics. - 1543-3080 .- 1543-5474. ; 5:3, s. 359-373
-
Tidskriftsartikel (refereegranskat)abstract
- The aims of this study were to investigate parent–child physical activity (PA) associations and whether children’s self-esteem or athletic competence mediates such associations.Methods:The study population comprised 1124 12-year-old children and their parents. Parents’ PA was assessed using the Baecke questionnaire and a question about sport participation. Children’s PA was assessed by questions about participation in sport and vigorous activities. The children’s self-esteem and athletic competence were assessed by Harter’s Self-Perception Profile for Adolescents.Results:Parents’ PA was strongly associated with their children’s PA. With 2 active parents, the odds ratio for their children to participate in sport was 3.9 (95% CI = 2.2–6.9, girls) and 8.8 (95% CI = 4.3–18.0, boys) compared with having inactive parents. Athletic competence partly mediated these associations.Conclusions:The family is an important target for interventions to increase PA among children, and it might be important to consider ways to reinforce children’s athletic competence.
|
|
| 20. |
|
|
| 21. |
|
|
| 22. |
|
|
| 23. |
|
|
| 24. |
- Krishnan, Shuba, et al.
(författare)
-
Metabolic Perturbation Associated With COVID-19 Disease Severity and SARS-CoV-2 Replication
- 2021
-
Ingår i: Molecular & Cellular Proteomics. - : Elsevier BV. - 1535-9476 .- 1535-9484. ; 20
-
Tidskriftsartikel (refereegranskat)abstract
- Viruses hijack host metabolic pathways for their replicative advantage. In this study, using patient-derived multiomics data and in vitro infection assays, we aimed to understand the role of key metabolic pathways that can regulate severe acute respiratory syndrome coronavirus-2 reproduction and their association with disease severity. We used multiomics platforms (targeted and untargeted proteomics and untargeted metabolomics) on patient samples and cell-line models along with immune phenotyping of metabolite transporters in patient blood cells to understand viral-induced metabolic modulations. We also modulated key metabolic pathways that were identified using multiomics data to regulate the viral reproduction in vitro. Coronavirus disease 2019 disease severity was characterized by increased plasma glucose and mannose levels. Immune phenotyping identified altered expression patterns of carbohydrate transporter, glucose transporter 1, in CD8+ T cells, intermediate and nonclassical monocytes, and amino acid transporter, xCT, in classical, intermediate, and nonclassical monocytes. In in vitro lung epithelial cell (Calu-3) infection model, we found that glycolysis and glutaminolysis are essential for virus replication, and blocking these metabolic pathways caused significant reduction in virus production. Taken together, we therefore hypothesized that severe acute respiratory syndrome coronavirus-2 utilizes and rewires pathways governing central carbon metabolism leading to the efflux of toxic metabolites and associated with disease severity. Thus, the host metabolic perturbation could be an attractive strategy to limit the viral replication and disease severity.
|
|
| 25. |
|
|
| 26. |
- Lôpez-Rubio, A., et al.
(författare)
-
Enhanced film forming and film properties of amylopectin using micro-fibrillated cellulose
- 2007
-
Ingår i: Carbohydrate Polymers. - : Elsevier BV. - 0144-8617 .- 1879-1344. ; 68:4, s. 718-727
-
Tidskriftsartikel (refereegranskat)abstract
- This work describes a novel approach to produce amylopectin films with enhanced properties by the addition of micro fibrillated cellulose (MFC). Aqueous dispersions of gelatinized amylopectin, glycerol (0-38 wt%) and MFC (0-10 wt%) were cast at ambient temperature and 50% relative humidity and, after 10 days of storage, the tensile properties were investigated. The structure of the composite films was revealed by optical, atomic force and transmission electron microscopy. The moisture content was determined by thermogravimetry and the temperature-dependent film rigidity was measured by thermal mechanical analysis. Synchrotron simultaneous small- and wide-angle X-ray measurements revealed that the solutions had to be heated to above 85 degrees C in order to achieve complete gelatinization. Optical microscopy and atomic force microscopy revealed uniformly distributed MFC aggregates in the films, with a length of 10-90 mu m and a width spanning from a few hundred nanometers to several microns. Transmission electron microscopy showed that, in addition to aggregates, single MFC microfibrils were also embedded in the amylopectin matrix. It was impossible to cast antylopectin films of sufficient quality with less than 38 wt% glycerol. However, when MFC was added it was possible to produce high quality films even without glycerol. The film without glycerol was stiff and strong but not brittle. It was suggested that this remarkable effect was due to its comparatively high moisture content. Consequently MFC acted both as a "conventional" reinforcement because of its fibrous structure and also indirectly as a plasticiser because its presence led to an increase in film moisture content.
|
|
| 27. |
|
|
| 28. |
|
|
| 29. |
- Nordqvist, Anneli, et al.
(författare)
-
Evaluation of the amino acid binding site of Mycobacterium tuberculosis glutamine synthetase for drug discovery
- 2008
-
Ingår i: Bioorganic & Medicinal Chemistry. - : Elsevier BV. - 0968-0896 .- 1464-3391. ; 16:10, s. 5501-5513
-
Tidskriftsartikel (refereegranskat)abstract
- A combination of a literature survey, structure-based virtual screening and synthesis of a small library was performed to identify hits to the potential antimycobacterial drug target, glutamine synthetase. The best inhibitor identified from the literature survey was (2S,5R)-2,6-diamino-5-hydroxyhexanoic acid (4, IC(50) of 610+/-15microM). In the virtual screening 46,400 compounds were docked and subjected to a pharmacophore search. Of these compounds, 29 were purchased and tested in a biological assay, allowing three novel inhibitors containing an aromatic scaffold to be identified. Based on one of the hits from the virtual screening a small library of 15 analogues was synthesized producing four compounds that inhibited glutamine synthetase.
|
|
| 30. |
|
|
| 31. |
|
|
| 32. |
- Nordqvist, Anneli, et al.
(författare)
-
Synthesis, biological evaluation and X-ray crystallographic studies of imidazo[1,2-a]-pyridine based Mycobacterium tuberculosis glutamine synthetase inhibitors
- 2012
-
Ingår i: MedChemComm. - : Royal Society of Chemistry (RSC). - 2040-2503 .- 2040-2511. ; 3:5, s. 620-626
-
Tidskriftsartikel (refereegranskat)abstract
- Based on an imidazo[1,2-a]pyridine hit from a high-throughput screen directed at the M. tuberculosis enzyme glutamine synthetase, a hit expansion was performed by synthesizing a series of analogs. A set of 16 molecules was first synthesized according to a statistical molecular design approach. One potent inhibitor was identified (IC50 = 3.0 µM), which led to the synthesis of 17 additional imidazo[1,2-a]pyridines in a follow-up study. Among these, several inhibitors were identified showing single digit micromolar potency. An X-ray structure of one of these revealed the binding mode of this class of inhibitors in the ATP-binding site, and allowed us to rationalize some of the structure-activity relationships observed.
|
|
| 33. |
- Nordqvist, David, et al.
(författare)
-
Enhancement of the wet properties of transparent chitosan-acetic-acid-salt films using microfibrillated cellulose
- 2007
-
Ingår i: Biomacromolecules. - : American Chemical Society (ACS). - 1525-7797 .- 1526-4602. ; 8:8, s. 2398-2403
-
Tidskriftsartikel (refereegranskat)abstract
- This report presents a new route to enhance the wet properties of chitosan-acetic-acid-salt films using microfibrillated cellulose (MFC). The enhancement makes it easier to form chitosan-acetic-acid-salt films into various shapes at room temperature in the wet state. Chitosan with MFC was compared with the well-known buffer treatment. It was observed that films containing 5 wt % MFC were visually identical to the buffered/unbuffered films without MFC. Field-emission scanning electron microscopy indicated that MFC formed a network with uniformly distributed fibrils and fibril bundles in the chitosan matrix. The addition of MFC reduced the risk of creases and deformation in the wet state because of a greater wet stiffness. The wet films containing MFC were also extensible. Although the stiffness, strength and extensibility were highest for the buffered films, the wet strength of the MFC-containing unbuffered films was sufficient for wet forming operations. The effects of MFC on the mechanical properties of the dry chitosan films were small or absent. It was concluded that the addition of MFC is an acceptable alternative to buffering for shaping chitosan films/products in the wet state. The advantages are that the "extra" processing step associated with buffering is unnecessary and that the film matrix remains more water-soluble.
|
|
| 34. |
- Odell, Luke R., et al.
(författare)
-
Functionalized 3-amino-imidazo[1,2-a]pyridines : A novel class of drug-like Mycobacterium tuberculosis glutamine synthetase inhibitors
- 2009
-
Ingår i: Bioorganic & Medicinal Chemistry Letters. - : Elsevier BV. - 0960-894X .- 1464-3405. ; 19:16, s. 4790-4793
-
Tidskriftsartikel (refereegranskat)abstract
- 3-Amino-imidazo[1,2-a]pyridines have been identified as a novel class of Mycobacterium tuberculosis glutamine synthetase inhibitors. Moreover, these compounds represent the first drug-like inhibitors of this enzyme. A series of compounds exploring structural diversity in the pyridine and phenyl rings have been synthesized and biologically evaluated. Compound 4n was found to be the most potent inhibitor (IC50 = 0.38 ± 0.02 μM). This compound was significantly more potent than the known inhibitors, L-methionine-SR-sulfoximine and phosphinothricin.
|
|
| 35. |
|
|
| 36. |
- Sharma, T., et al.
(författare)
-
Development of Hillchol (R), a low-cost inactivated single strain Hikojima oral cholera vaccine
- 2020
-
Ingår i: Vaccine. - : Elsevier BV. - 0264-410X. ; 38:50, s. 7998-8009
-
Tidskriftsartikel (refereegranskat)abstract
- Cholera remains an important global health problem with up to 4 million cases and 140,000 deaths annually. Oral cholera vaccines (OCVs) are now a cornerstone of the WHOs "Ending Cholera - A Global Roadmap to 2030" global program for the eventual elimination of cholera. There are currently three WHO prequalified OCVs available, Dukoral (R), Shanchol (R) and Euvichol-Plus (R). These vaccines are effective but due to a multiple strain composition and two different methods of inactivation, are complex and costly to manufacture. We describe here the characterization and industrial scale development of Hillchol (R); a novel, likely affordable single-component OCV for low and middle-income countries. Hillchol (R) consists of formalin-inactivated bacteria of a stable recombinant Vibrio cholerae O1 El Tor Hikojima serotype strain expressing approximately 50% each of Ogawa and Inaba O1 LPS antigens. The novel OCV can be manufactured on an industrial scale at a low cost. Hillchol (R) was well tolerated in animal toxicology studies and shown to have non-inferior oral immunogenicity in mice for both intestinalmucosal and serological immune responses when compared with a WHO-prequalified OCV. The optimized production of this single component OCV will reduce cost of OCV production and thus substantially increase vaccine availability. Based on these results, Hillchol (R) has been produced at a GMP facility and used successfully for clinical phase I/II studies. (C) 2020 MSD Wellcome Trust Hilleman Laboratories Pvt Ltd. Published by Elsevier Ltd.
|
|
| 37. |
|
|
| 38. |
|
|
| 39. |
|
|
| 40. |
- Terrinoni, Manuela, et al.
(författare)
-
A thermostable, dry formulation inactivated Hikojima whole cell/cholera toxin B subunit oral cholera vaccine
- 2023
-
Ingår i: Vaccine. - 0264-410X. ; 41:21, s. 3347-3357
-
Tidskriftsartikel (refereegranskat)abstract
- The feared diarrheal disease cholera remains an important global health problem. Use of oral cholera vac-cine (OCV) from a global stockpile against both epidemic and endemic cholera is a cornerstone in the World Health Organisations (WHOs) global program for "Ending cholera by 2030". Three liquid inacti-vated whole-cell OCVs (Dukoral (R), ShancholTM, and Euvichol-Plus (R)) are WHO prequalified and have proved to be safe and effective. However, their multicomponent composition and cold-chain requirement increase manufacturing, storage and transport costs. ShancholTM and Euvichol-Plus (R) OCVs used in WHOs global vaccine stockpile also lack the protective cholera toxin B-subunit (CTB) antigen present in Dukoral (R), which results in suboptimal efficacy.WHOs Global Task Force on Cholera Control (GTFCC) has identified a thermostable, dry formulation vaccine as a priority for further OCV development. We describe here the development of such a vaccine, based on a lyophilized mixture of a single strain of formalin-killed Hikojima bacteria together with a low-cost, recombinantly produced CTB. The new vaccine, which is easy and inexpensive to manufacture, could be stored for at least 26 months at 25 degrees C and for at least 8 months at 40 degrees C with preservation of cell mor-phology and with no loss of protective Ogawa and Inaba lipopolysaccharides or CTB. It also proved to be well tolerated and to have equivalent oral immunogenicity in mice as ShancholTM and Dukoral (R) OCVs with regard to both serum and intestinal-mucosal antibody responses.
|
|
| 41. |
|
|
